Last reviewed · How we verify
Menveo®/Menactra®
Menveo®/Menactra® is a Conjugate vaccine Biologic drug developed by Massachusetts General Hospital. It is currently FDA-approved.
Menveo® and Menactra® are conjugate vaccines that stimulate the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y.
Menveo/Menactra is a vaccine antigen that targets Neisseria meningitidis serogroups A, C, Y, and W. It is a conjugate vaccine that uses oligosaccharides from the bacteria, conjugated to Corynebacterium diphtheriae CRM197, to stimulate an immune response.
At a glance
| Generic name | Menveo®/Menactra® |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroups A, C, W, and Y |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
These vaccines contain polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, which are conjugated to a carrier protein to enhance immunogenicity.
Approved indications
Common side effects
- Pain at injection site
- Redness at injection site
- Swelling at injection site
- Headache
- Fatigue
- Myalgia
- Fever
Key clinical trials
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (PHASE1, PHASE2)
- Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (PHASE4)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents (PHASE2)
- Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menveo®/Menactra® CI brief — competitive landscape report
- Menveo®/Menactra® updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about Menveo®/Menactra®
What is Menveo®/Menactra®?
How does Menveo®/Menactra® work?
Who makes Menveo®/Menactra®?
What drug class is Menveo®/Menactra® in?
What development phase is Menveo®/Menactra® in?
What are the side effects of Menveo®/Menactra®?
What does Menveo®/Menactra® target?
Related
- Drug class: All Conjugate vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroups A, C, W, and Y
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing